Qureight Closes $20M to Advance AI Imaging

The big picture: Cambridge MedTech company Qureight has closed a £15m ($20m) Series B funding round led by Molten Ventures. The company, founded in 2020, provides end-to-end imaging and precision endpoints for clinical trials, with a specific focus on lung and heart disease. The round was significantly oversubscribed, indicating strong investor confidence.

Why it matters:

• Accelerating drug discovery: Qureight’s technology aims to help biopharma develop better medicines faster by leveraging advanced imaging and precision endpoints.
• Addressing unmet needs: The company focuses on lung and heart diseases, targeting critical areas with high unmet medical needs in clinical research.
• AI-driven innovation: The investment highlights the growing role of AI, powered by real-world data, in transforming clinical research and accelerating medical innovation.

How it works:

• 3D deep-learning imaging: Qureight is expanding its 3D deep-learning imaging portfolio to enhance its capabilities in analyzing complex medical images.
• Chest foundation model: New capital will establish an AI imaging lab and accelerate the development of a 3D chest foundation model.
• Enterprise-grade platform: The company offers an enterprise-grade imaging platform designed to provide accurate and reliable data for clinical trials.

The catch: The market for AI-powered clinical trial solutions is highly competitive, with numerous companies vying to optimize drug discovery and development. Qureight will need to maintain its leadership in specific niches like lung fibrosis while successfully expanding into new therapeutic markets to sustain growth against established players and emerging startups.